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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) patients frequently present with borderline resectable
disease, which can be due to invasion of the portal/superior mesenteric vein (PV/SMV). Here, we analyzed this
group of patients, with emphasis on short and long-term outcomes.
Methods: 156 patients who underwent a resection for PDAC were included in the analysis and sub-stratified into a
cohort of patients with PV/SMV resection (n = 54) versus those with standard surgeries (n = 102).
Results: While venous resections could be performed safely, there was a trend towards shorter median survival in the
PV/SMV resection group (22.7 vs. 15.8 months, p = 0.157). These tumors were significantly larger (3.5 vs 4.3 cm; p = 0.026)
and margin-positivity was more frequent (30.4 % vs 44.4 %, p = 0.046).
Conclusion: Venous resection was associated with a higher rate of margin positivity and a trend towards shorter survival.
However, compared to non-surgical treatment, resection offers the best chance for long term survival.
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Background
The extension of the resectability criteria for pancre-
atic adenocarcinoma (PDAC) has been intensively
discussed in the last decade. It has been shown that
arterial resections significantly increase mortality [1]
but that resections for presumed invasion of the
superior mesenteric/portal vein axis (PV/SMV,
“venous resections”) can be carried out safely without
increased morbidity/mortality. In addition, taken all
patients together, venous resections are not associated
with an inferior survival than standard resections [2].
However, some groups have argued that true (in con-
trast to suspected) venous infiltration was associated
with significantly shorter survival [3–6] while others
have not reproduced these results [7–9]. Nonetheless the
data on venous resections, especially those on perioperative
outcome, have changed clinical practice in that these resec-
tions have become the standard for such tumors. Despite
these technical improvements and the wide-spread intro-
duction of adjuvant (and neoadjuvant) chemotherapy,
prognosis has not much changed [10, 11].
At the same time, outcome prediction remains challen-
ging because a considerable subgroup of patients probably
does not benefit from surgery. This is because it is difficult
to predict pre-/intraoperative undetectable (“subclinical”)
metastatic disease and in line with this it is currently im-
possible to predict the biological behaviour of the tumors.
Thus, there is currently a gap between our knowledge of
the biology of PDAC and the technical/surgical advances.
This is also underscored by a recent hypothesis that tumor
size (and thus likelihood of vascular infiltration) and the
time of metastasis are closely linked. Here, an exponential
probability for metastatic spread was calculated depending
on the size of the primary tumor [12]. Thus, many tumors
deemed resectable will probably already have metastasized,
though clinically not detectable [12]. In this study, we ana-
lysed our cohort of resected PDAC patients with special
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emphasis on venous resection/involvement and tumor
biology/outcome.
Methods
The Institutional Review Board (Ethikkommission der
Medizinischen Fakultät der Technischen Universität
München, Munich, Germany) approved prospective
and retrospective data collection as well as tissue col-
lection (1926/07 and 5893/13). Written informed con-
sent was obtained from all patients. Analysis was
conducted on an anonymized data set.
Database and recorded parameters
In July 2007, we established a prospective database for the
assessment of patients who underwent surgery for pancre-
atic diseases. The following parameters were recorded:
tumor entity, age, gender, pre-operative weight loss, the fol-
lowing preoperative blood parameters: GPT/ALAT, GOT/
ASAT, bilirubin, AP, gamma-GT and CA19-9, comorbidi-
ties (pre-operative presence of diabetes mellitus, previous
or concomitant cancer diagnoses other than PDAC, a his-
tory of (acute/chronic) pancreatitis, medical co-morbidities
as reflected by the ASA score), presence of preoperative
jaundice and/or ERCP/bile duct/pancreatic duct stenting,
treatment (e.g. surgical technique, (neo-)adjuvant therapy),
intraoperative blood transfusion(s), duration of operation,
resection (and reconstruction) of the portal/superior mes-
enteric vein, histologically confirmed presence of venous
invasion, size of the tumor (T), lymph node status (N),
resection margin (R), grading (G), UICC-classification,










M 27 (50.0 %) 61 (59.8 %)
F 27 (50.0 %) 41 (40.2 %)




1 3 (5.6 %) 8 (7.8 %)
2 31 (57.4 %) 58 (56.9 %)
3 20 (37.0 %) 36 (35.3 %)
Diabetes mellitus 16 (29.6 %) 27 (26.5 %) 0.67
Bile duct stent 18 (33.3 %) 39 (38.2 %) 0.54
Pancreatitis 2 (3.7 %) 12 (11.8 %) 0.09
Neoadjuvant treatment 4 (7.4 %) 6 (5.9 %) 0.43
Type of Surgery 0.001
pp-Whipple 25 (46.3 %) 63 (61.7 %)
cl-Whipple 8 (14.8 %) 6 (5.9 %)
TP 16 (29.6 %) 9 (8.8 %)
DP 5 (9.3 %) 22 (21.7 %)
DPH 0 2 (1.9 %)
Vein resection technique
End-to-End-Anastomosis 33 (61.1 %)
Wedge-Resection 15 (27.8 %)
goretex™ graft 6 (11.1 %)
Operative time, mean
(STD), min.
378 (103) 317 (85) <0.0012
Blood transfusion 9 (16,7 %) 4 (4,0 %) 0.012





G1 1 (1.8 %) 8 (7.8 %)
G2 25 (46.3 %) 41 (40.2 %)
G3 28 (51.9 %) 53 (52.0 %)
T-stage 0.36
T1 1 (1.8 %) 4 (3.9 %)
T2 3 (5.6 %) 7 (6.9 %)
T3 41 (75.9 %) 83 (81.4 %)
T4 9 (16.7 %) 8 (7.8 %)
Tumor size in cm
(median, min-max)
4.3 1.5-12 3.5 1.2-8.5 0.0263
Table 1 Patients characteristics, venous resection vs. no venous
resection (Continued)
Nodal status 0.82
0 16 (29.6 %) 32 (31.4 %)
1 38 (70.4 %) 70 (68.6 %)
Number of lymph nodes
(median, min-max)
21 (5–62) 20 (7–54) 0.92
Resection margins 0.0464
R0 22 (40.8 %) 60 (58.8 %)
R1 24 (44.4 %) 31 (30.4 %)
R2 0 1 (1.0 %)
Rx 8 (14.8 %) 10 (9.8 %)
Pathology report:
venous infiltration
no 8 (14.8 %)
yes 19 (35.2 %)
unkown 27 (50.0 %)
1X2-test; 2Student’s t-test; 3Mann–Whitney-U-test; 4X2-test: R0 vs. R1
Abbreviations: pp-Whipple pylorus-preserving Whipple (=pp-partial
pancreaticoduodenectomy), cl-Whipple “classical” Whipple, TP total
pancreatectomy, DP distal pancreatectomy, DPH DP plus partial pancreatic
head resection, STD standard deviation
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postoperative complications (according to the Clavien-
Dindo classification [13]). The characteristics of the patients
in the different cohorts are depicted in Table 1. Resectabil-
ity criteria were defined according to the NCCN [14]. Lo-
cally advanced unresectable tumors were treated with
neoadjuvant treatment protocols as decided in a multidis-
ciplinary tumor board. Occasionally, patients were referred
to our hospital after neoadjuvant or palliative intended ther-
apy for borderline or locally advanced tumors. Lymph node
dissection was standardized for all cases as described in the
recent ISGP definition [15]. Venous resection was not con-
sidered a contraindication for surgery. The described ap-
proach did not change during the study period.
Inclusion and exclusion criteria
We retrospectively identified 209 patients who underwent
an elective pancreatic resection with a final histopatho-
logical diagnosis of PDAC between 07/2007 and 07/2011
(Fig. 1). The following patients were excluded from the
analysis: UICC stage IV disease (n = 19), patients who
were resected for local tumor recurrence (n = 3), patients
on whom arterial resections were performed (n = 6), pa-
tients with a history of another cancer disease (n = 17) and
patients who died because of surgery-related complica-
tions within 4 months from surgery (extension as sug-
gested by Strasberg et al. [16], n = 6); three patients were
lost to follow-up. Due to the relatively small patient cohort
and considering the 2:1 ratio of the non-vein resected to
the vein resected group, we opted for the inclusion of all
patients and against a matched case analysis.
At the time of analysis, 17 out of 54 patients in the
group of vein-resected patients and 34 out of 102 patients
in the standard resection group were alive. Median follow-
up for all patients was 20.8 months (3.3-69.8 months) and
median follow-up for patients alive was 37.7 months
(21.0-69.6 months). Patient charts were reviewed for
Fig. 1 Inclusion and exclusion criteria. Flow-chart of inclusion and exclusion criteria. The prospective database was retrospectively searched according to
the criteria as described in the Methods section. Two cohorts of patients were defined: short- and long-term survivors and patients on whom standard
resections or resections with vein resections were performed
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whether or not a resection of the PV/SMV (wedge re-
section, complete resection with end-to-end anasto-
mosis or interposition of a goretex™ graft) had been
performed. In this cohort of patients, preoperative
imaging (computed tomography of the abdomen or
magnetic resonance imaging/magnetic resonance cho-
langiopancreaticography (MRI/MRCP)) was evaluated
to estimate sensitivity and specificity in regard to de-
fining the presence of true venous invasion (versus an
inflammatory/desmoplastic reaction at the PV/SMV).
Statistics
Continuous variables are reported as means ± SD or me-
dian (min.-max./95 %-CI), and were compared using a Stu-
dent’s t-test or a Mann–Whitney-U-test, as appropriate.
Categorical variables are summarized as frequency counts
and percentages and were compared using Fischer’s exact
test or Pearsons’s chi-square test, as appropriate. Overall
survival was defined as time from resection until death or
until last follow-up.
Survival analysis was performed using the Kaplan-Meier
method; differences were evaluated with the log rank test.
A two-sided P value of <0.05 was considered as significant.
All statistical analyses were performed using IBM SPSS,
v20 for Windows (IBM Inc., USA).
Results
Analysis of venous resection
The cohort of patients on whom venous resections
have been performed was compared with the cohort of
patients on whom standard pancreatic resections have
been performed (Table 1). Except for late portal vein
thrombosis (7 cases in the venous resection cohort
versus one case in standard resection group), postoper-
ative complications and (early and late) mortality were
comparable in both groups (Table 2). These findings are
in line with published data [2, 7, 17, 18], demonstrating
that venous resections can be performed safely. Interest-
ingly however, significantly more resections were margin-
positive (i.e. R1; 44.4 % vs. 30.4 %, p = 0.046) in the venous
resection cohort of patients. This might be a reflection of
Table 2 Postoperative complications (30-days), venous resection vs. no venous resection
Venous resection VR (n = 54) No venous resection NVR (n = 102) p-value1
Postoperative complications2 0.38
Grade I 12 22.2 % 15 14.71 % 0.19
Grade II3 19 35.2 % 38 37.3 % 0.86
Grade III 8 14.8 % 9 8.8 % 0.28
Grade IV 1 1.8 % 1 1.0 % 1.00
120 day mortality4 3 5.3 % 3 2.9 % 0.37
Portal vein thrombosis
30 days 1 1.8 % 1 1.0 % 0.69
total 7 13.0 % 1 1.0 % 0.001
Pancreatic fistula, grade C 2 3.7 % 4 3.9 %
Lymph fistula 2 3.7 % 3 2.9 %
Delayed gastric emptying 6 11.1 % 4 3.9 % 0.09
Diarrhea 4 7.4 % 4 3.9 %
Intraabdominalabscess 2 3.7 % 5 4.9 %
Cholangitis 3 5.6 % 15 14.7 % 0.11
Wound infection 3 5.6 % 8 7.8 %
Liver ischemia 1 1.8 % 0 0.0 %
Bleeding 2 3.7 % 0 0.0 %
Re-operation 2 3.7 % 3 2.9 %
Pneumonia 0 0.0 % 1 1.0 %
Urinary tract infection 2 3.7 % 2 2.0 %
Cardiac dysfunction 1 1.8 % 3 2.9 %
1X2-test
2Clavien-Dindo-Classification
3VR: 9 patients (47.4 %) only blood transfusion. 6 patients (31.5 %) antibiotics. 1 patient (5.3 %) blood transfusion and antibiotics; without VR: 4 patients (10.5 %)
only blood transfusion. 21 patients (55.3 %) only antibiotics; 4 patients (10.5 %) blood transfusion and antibiotics
4VR (n = 57) vs. NVR (n = 105)
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Table 3 Characteristics of 27 patients with vein resection and confirmed pathology report
No venous invasion (n = 8) Venous invasion (n = 19) p-value1
Sex 0.33
M 5 (62.3 %) 8 (42.1 %)
F 3 (37.4 %) 11 (57.9 %)
Age, mean (STD), yrs 61.7 (13.2) 65.0 (10.3) 0.48
Preoperative performance status
ASA 0.23
1/2 4 (50.0 %) 14 (73.7 %)
3 4 (50.0 %) 5 (26.3 %)
Diabetes mellitus 1 (12.5 %) 6 (31.6 %) 0.41
Bile duct stent 2 (25.0 %) 11 (57.9 %) 0.23
Type of surgery 0.55
ppWhipple/cl-Whipple 6 (75.0 %) 12 (63.2 %)
TP 2 (25.0 %) 7 (36.8 %)
Vein resection technique 0.19
End-to-End anastomosis 6 (75.0 %) 15 (78.9 %)
Wedge- Resection 2 (25.0 %) 1 (5.3 %)
goretex™ graft 0 3 (15.8 %)
Operative time, mean (STD), min. 416 (42) 379 (85) 0.2222
c3 0.52
Grade I/II 4 (50.0 %) 11 (57.9 %)
Grade III/IV 2 (25.0 %) 4 (21.1 %)
Pathological findings
Tumor grade of differentiation 0.47
G1/G2 6 (75.0 %) 9 (47.4 %)
G3 2 (25.0 %) 10 (52.6 %)
T-stage 0.001
T1/T2 4 (50.0 %) 0
T3/T4 4 (50.0 %) 19 (100.0 %)
Nodal status 0.038
N0 6 (75.0 %) 6 (31.6 %)
N1 2 (25.0 %) 13 (68.4 %)
Resection margins 0.36
R0 4 (50.0 %) 6 (31.6 %)
R1 (incl. RX) 4 (50.0 %) 13 (68.5 %)
Localization of tumor 0.099
Pancreatic head 7 (87.5 %) 14 (73.7 %)
Multifocal 1 (12.5 %) 5 (26.3 %)
Pre-operative prediction venous infiltration
CT/MRT+ 5 11 Sensitivity: 0.69
CT/MRT- 2 5 Specificity: 0.29
1X2-test; 2Student’s t-test; 3Clavien-Dindo-Classification
Abbreviations: pp-Whipple pylorus-preserving Whipple (=pp-partial pancreaticoduodenectomy), cl-Whipple “classical” Whipple, TP total pancreatectomy,
STD standard deviation
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larger tumors in the patients with venous resections
(4.3 cm vs. 3.5 cm, p = 0.026, Table 1). While some groups
demonstrated that true tumor cell invasion of the PV/
SMV negatively impacted on prognosis [3–6, 19], others
have denied such an association [7–9]. We thus re-
assessed the histo-pathology reports on invasion/no-
invasion of the vein (Table 1). In those cases were data
on vein invasion was available, 30 % were tumor cell-
negative whereas in 70 %, tumor cell invasion of the
vein was seen. We then analyzed the patients with
confirmed invasion of the vein vs. no-invasion; here,
no significant differences in regard to preoperative
markers, operative time or surgical technique were
found (Table 3). Comparable to the whole cohort of
venous resection patients, postoperative complications
(including late surgical related mortality) occurred at
similar frequencies in both groups. Further analysis
however demonstrated that the tumors in the true
venous invasion group of patients were significantly
more advanced (T3/4 tumors in the no-venous inva-
sion vs. venous invasion groups: 4/8 vs. 19/19, p =
0.001, Table 3). In line with these findings that
implicated more advanced tumors in the true invasion
group, significantly more patients had lymph node
metastases when the vein was truly infiltrated
(Table 3). CT or MRI scans were available in our
digital imaging system from 23 of 27 patients. Radio-
logical assessment of these scans revealed that CT or MRI
predicted true invasion of the vein only at a sensitivity of
69 % and a specificity of 29 % (Table 3). Though the pa-
tient number is low, these data demonstrate the difficulties
in preoperative prediction of the presence/extent of PV/
SMV invasion.
Survival following venous resections
To determine the extent of selection bias in the venous
resection cohort of patients, we stratified these according
to the UICC classification and plotted the subgroups fol-
lowing Kaplan-Meier survival analysis (Fig. 2a). This ana-
lysis demonstrates that the general prognosis of this
cohort of patients is accurately predicted by the UICC.
Thus, we assumed that selection bias was not overly
strong in our cohort of patients and considered that the





UICC I: >45.5 months (n=8)
UICC IIa: 52.0 months (n=39)
UICC IIb: 17.6 months (n=92)
UICC III: 9.1 months (n=17)
NVR: 22.7 months (n=102)
VR: 15.8 months (n=54)
pp-Whipple: 22.8 months (n=26)
DP: 28.0 months (n=5)
cl-Whipple: 19.4 months (n=9)
TP: 9.1 months (n=14)
A: G1/G2, NVR: 39.9 months (n=49)
B: G1/G2, VR: 24.5 months (n=53)
C: G3, NVR: 15.5 months (n=26)
D: G3, VR: 12.5 months (n=28)
Fig. 2 Survival analysis. a, Survival according to the UICC stages was assessed using the Kaplan-Meier method and the log rank test. The overall p-value is
0.001. b, Survival in the patient groups with standard (no venous resection, NVR) and with venous resection (VR) was compared using Kaplan-Meier curves
and the log rank test; p= 0.157. c, Survival according to different operative techniques was assessed using Kaplan-Meier curves and the log rank test. TP:
total pancreatectomy; DP: distal pancreatectomy; pp-Whipple: partial, pylorus-preserving pancreaticoduodenectomy; cl-Whipple: “classical” Whipple, partial
pancreaticoduodenectomy. d, Comparisons between the following groups were done using the Kaplan-Meier method and log rank testing: G1/2 without
vein resection (a), G1/2 with vein resection (b), G3 without vein resection (c), G3 vein resection (d). The overall p-value is <0.001. a vs c: p< 0.001; b vs
d: p= 0.023
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Though there was a trend towards shorter survival
of patients in whom venous resections had to be per-
formed, this was not statistically significant (median
survival 22.7 vs. 15.8 months, Fig. 2b; p = 0.157).
Pathologically confirmed invasion of the vein was not
relevant for prognosis. In addition, patients on whom
a total pancreatectomy had to be performed lived
shorter than those with pancreaticoduodenectomy or dis-
tal pancreatectomy (9.1 months versus 19.4 - 28 months,
Fig. 2c).
Next, we analyzed tumor grade as a surrogate marker for
tumor biology. Patients with well- and moderately differen-
tiated PDACs lived significantly longer than those with
poorly differentiated tumors (overall p < 0.001, median
survival 39.9 vs. 15.5 months, p < 0.001; Fig. 2d), and this
stratification was also significant in the venous resection
cohort (median survival 24.5 vs. 12.5 months, p = 0.023).
Discussion
The data presented in this paper confirm previously pub-
lished results on portal vein resections during surgery for
pancreatic adenocarcinoma, i.e. that it can be performed
safely without increased morbidity and (early and late)
mortality. There was a trend towards shorter survival and
more frequent margin-positivity in the group of patients in
whom venous resections had been performed. However,
this was mainly a result of the outcomes after combined
total pancreatectomy and portal vein resection. Such opera-
tions were only performed if a pancreaticoduodenectomy
or a distal pancreatectomy were technically impossible or
not sufficient to achieve macroscopic tumor clearance. This
is also reflected in the finding that outcomes were worse in
larger tumors. For partial pancreaticoduodenectomy and
distal pancreatectomy with venous resections, there were
no considerable differences compared to the respective
standard resections. Thus, our data are in line with previous
publications and support the concept that partial resection
of the PV/SMV is justified to achieve negative margins and
thereby better local control [20, 21]. However, as patients
undergoing total pancreatectomy plus PV/SMV resection
had worse outcomes, it might be argued that this group of
patients with centrally located, large tumors, for whom total
pancreatectomy is anticipated/likely, should not be oper-
ated upfront, but might be better candidates for neoadju-
vant treatment.
Our study also highlights the prognostic importance
of tumor biology, using grading as a surrogate marker.
Obviously, tumor biology rather than tumor location
(and vascular abutment/invasion) is a stronger prog-
nostic factor. This is also supported by recent data on
long term survival after PDAC resections. Here, tumor
biology was identified as the most important factor,
with a significant number of long term survivors having
a positive margin status and lymph node metastasis
[11]. Further studies are required to better predict and
understand tumor biology and stratify patients that
benefit most from extensive surgical procedures.
There are some drawbacks of the present study.
Although standardized histopathological reporting with
special emphasis on resection margins had been intro-
duced in our center in 2007 [22–24], venous involve-
ment had not been assessed in all cases. Thus, data
regarding preoperative diagnostic accuracy and true
venous infiltration have to be interpreted cautiously.
Conclusion
In summary, our data support the current clinical practice
of operating on patients with suspected involvement of the
PV/SMV, and to perform (partial) resection of the PV/SMV
if necessary to achieve tumor-free margins.
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